Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Update

Key Points

• Barinthus Biotherapeutics PLC saw a significant increase in short interest, rising by 53.5% to a total of 123,100 shares as of September 30th.
• The company's stock traded down 6.3% to $1.30, with a 50-day moving average of $1.25 and a 1-year high of $2.92.
• Analysts have mixed ratings on the stock, with an average rating of "Hold" and a price target of $3.00, alongside a recent "sell (d-)" rating from Weiss Ratings.

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS - Get Free Report) was the recipient of a large growth in short interest in September. As of September 30th, there was short interest totaling 123,100 shares, a growth of 53.5% from the September 15th total of 80,200 shares. Based on an average daily volume of 1,280,000 shares, the short-interest ratio is currently 0.1 days. Approximately 0.3% of the shares of the stock are short sold. Approximately 0.3% of the shares of the stock are short sold. Based on an average daily volume of 1,280,000 shares, the short-interest ratio is currently 0.1 days.

Barinthus Biotherapeutics Trading Down 6.3%

BRNS stock traded down $0.09 during mid-day trading on Wednesday, hitting $1.30. 39,984 shares of the company were exchanged, compared to its average volume of 260,591. The business has a 50 day simple moving average of $1.25 and a 200-day simple moving average of $1.10. Barinthus Biotherapeutics has a 1-year low of $0.64 and a 1-year high of $2.92.

Barinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.23). As a group, analysts predict that Barinthus Biotherapeutics will post -1.38 earnings per share for the current year.

Hedge Funds Weigh In On Barinthus Biotherapeutics

An institutional investor recently bought a new position in Barinthus Biotherapeutics stock. HighTower Advisors LLC acquired a new position in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 37,450 shares of the company's stock, valued at approximately $36,000. HighTower Advisors LLC owned about 0.09% of Barinthus Biotherapeutics as of its most recent SEC filing. 25.20% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of Barinthus Biotherapeutics in a report on Tuesday, October 14th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $3.00.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.